Last Week’s Top 3 Most Read Posts On Pulmonary Fibrosis

Phase II Trial for Gilead’s IPF Therapy Simtuzumab Terminated After DMC Recommendation

Gilead Sciences, Inc. recently announced in a press release that it is stopping its RAINIER Phase II clinical trial testing the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis (IPF), noting that the experimental therapy did not demonstrate efficacy in treating the disease. Simtuzumab is a humanized monoclonal…

Pulmonary Fibrosis: Breathing with Help

https://www.youtube.com/watch?v=a9D2HUyud-k   Learn more about Pulmonary Fibrosis: http://bit.ly/1lfMsiZ Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of…

Pulmonary Fibrosis Among Top Projects in Expanding Research Partnership

MedImmune, AstraZeneca’s biologic research and development arm, announced that it is expanding its collaboration with the University of California, San Francisco (UCSF), to focus on basic research and translational sciences into diseases involving the Respiratory, Inflammation and Autoimmunity (RIA) fields. The partnership continues joint work begun in 2014, and the two will initiate about a half-dozen research projects…

IPF: Pirfenidone & Nintedanib as Treatment

“Dr. Timothy Whelan, Medical Director of the Lung Transplant Program from the Medical University of South Carolina, provides advice for two new drugs, Pirfenidone and Nintedanib, to slow the progression of IPF.” Read more about IPF and approved therapies: http://bit.ly/1lfMsiZ…

7 Articles On #Esbriet

1. Genentech’s PF Drug Esbriet Shown To Lower Mortality Rates in New Study   Read the article here: http://bit.ly/1URSd1G 2. Esbriet’s Promise and Potential as a PF Therapy   Read the article here: http://bit.ly/1kub6MJ 3. Phase III Trials…

IPF Disease Carries High Economic and Healthcare Burden

A retrospective study analyzing data on insurance claims from patients with idiopathic pulmonary fibrosis (IPF) revealed that the disease is associated with a significant economic and healthcare burden. The study, titled “Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study,” was published in the…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums